Neoplasms

All Conditions

Rare Diseases

Sarcoma

Pelvic Neoplasms

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

Treatment will take approximately 2 weeks.

Stereotactic body radiotherapy

-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up

Research blood draw

Pamela Samson, M.D.

This is a study evaluating the safety and efficacy of Lattice SBRT for patients with large tumors (≥ 4.5 cm) planning to undergo palliative radiotherapy.

At least 10 participants will be enrolled in each cohort (soft tissue sarcomas, thoracic cancers, abdominal, and pelvic cancers).

Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

A Trial of Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

-The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities

* 10-item questionnaire assessing current self-reported physical function
* Answers range from 1-cannot do to 5=not at all/without any difficulty
* Score ranges from 10-50 with a higher score indicating better physical function

* 2-item questionnaire assessing current self-reported overall physical function
* Answers range from 1=poor/not all all to 5=excellent/completely
* Score ranges from 2-10 with a higher score indicating better global health physical function

* 29-item questionnaire assessing current self-reported anxiety
* Answers range from 1-never to 5=always
* Score ranges from 29-145 with a lower score indicating less anxiety

* 4-item questionnaire assessing current self-reported depression
* Answers range from 1=never to 5=always
* Score ranges from 4-20 with a lower score indicating less depression

-The Numeric Pain Scale is an 11-point scale for patient self-reporting of pain

Goldman Sachs Foundation (Emerson Collective)

Washington University School of Medicine

SBRT

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Participants must have received treatment and had a 6 month disease assessment to be evaluable for this outcome measure.

Spots Global Cancer Trial Database for Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial